Systemic inflammatory response syndrome and multiple organ dysfunction in patients with acute tumor lysis syndrome

Clinics

Volumn 64, Issue 5, 2009, Pages 479-481

  Soares, Márcio ^a   Feres, Guilherme A ^a   Salluh, Jorge I F ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; ADULT; FEMALE; HUMAN; LETTER; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; RETROSPECTIVE STUDY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR LYSIS SYNDROME;

ACUTE DISEASE; ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; RETROSPECTIVE STUDIES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR LYSIS SYNDROME;

EID: 67749130673     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322009000500016     Document Type: Letter

References (12)

1. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004;116:546-54.
2. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3-11.
3. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992; 101:1644-55.
4. Hijiya N, Metzger ML, Pounds S, Schmidt JE, Razzouk BI, Rubnitz JE, et al. Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia. Pediatr Blood Cancer. 2005;44:63-9.
5. Soares M, Salluh JI. Validation of the SAPS 3 admission prognostic model in patients with cancer in need of intensive care. Intensive Care Med. 2006;32:1839-44.
6. Le Gall J-R, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957-63.
7. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707-10.
8. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128-40.
9. Fink MP, Evans TW. Mechanisms of organ dysfunction in critical illness: report from a Round Table Conference held in Brussels. Intensive Care Med. 2002;28:369-75.
10. Cowley HC, Bacon PJ, Goode HF, Webster NR, Jones JG, Menon DK. Plasma antioxidant potential in severe sepsis: a comparison of survivors and nonsurvivors. Crit Care Med. 1996;24:1179-83.
11. Sanchez-Lozada LG, Nakagawa T, Kang DH, Feig DI, Franco M, Johnson RJ, et al. Hormonal and cytokine effects of uric acid. Curr Opin Nephrol Hypertens. 2006;15:30-33.
12. Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg. 1992;215:356-62.